MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
EASL LiverTree™. Harrison S. Apr 13, 2018; 210658
Topic: Thyroid hormone analogs
Dr. Stephen Harrison
Dr. Stephen Harrison
Access this content in seconds by registering and creating a Free EASL Global Account here.

This content is open access (EASL members and nonmembers) as part of the educational mission of EASL.

You may also access EASL content "anytime, anywhere" with the FREE EASL LiverTree App for iOS and Android.
Full presentation open to non EASL members:
Learning Objectives
Abstract
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:
- Learn about effects of a THR-B agonist MGL-3196 in patients with NASH (safety/efficacy)
GS-009
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings